Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.

Clin Cancer Res 2019 Jul 5;25(13):3811-3817. Epub 2019 Apr 5.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Purpose: VEGFR2-directed therapy is commonly used to treat metastatic esophagogastric cancer, but disease progresses in most patients within months. Therapeutic resistance is likely mediated in part by co-occurring amplifications of the genes for multiple oncogenic receptor tyrosine kinases (RTK). We therefore tested the efficacy of combined inhibition of VEGFR1-3, PDGFα/β, and FGFR1-3 using nintedanib.

Patients And Methods: Patients with metastatic esophagogastric adenocarcinoma and disease progression on first-line chemotherapy were treated with nintedanib 200 mg twice daily. The primary endpoint was progression-free survival (PFS) at 6 months; secondary endpoints included tumor response and safety. Tumor biopsies were profiled by targeted capture next-generation sequencing (NGS) to identify molecular predictors of drug response.

Results: The study achieved its primary endpoint; 6 of 32 patients (19%) were progression-free at 6 months. With a median follow-up of 14.5 months among survivors, median overall survival (OS) was 14.2 months [95% confidence interval (CI), 10.8 months-NR]. Nintedanib was well tolerated; grade ≥ 3 toxicities were uncommon and included grade 3 hypertension (15%) and liver enzyme elevation (4%). alterations were identified in 18% of patients but were not predictive of clinical outcome on nintedanib therapy. Alterations in cell-cycle pathway genes were associated with worse median PFS (1.61 months for patients with cell-cycle pathway alterations vs. 2.66 months for patients without, = 0.019).

Conclusions: Nintedanib treatment resulted in modest disease stabilization in patients with metastatic esophagogastric cancer. Alterations in cell-cycle pathway genes and increased global copy-number alteration (CNA) burden warrant further study as prognostic or predictive biomarkers.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606369PMC
July 2019
12 Reads

Publication Analysis

Top Keywords

metastatic esophagogastric
12
cell-cycle pathway
12
esophagogastric cancer
12
pathway genes
8
alterations cell-cycle
8
pdgfα/β fgfr1-3
8
patients metastatic
8
efficacy combined
8
months patients
8
primary endpoint
8
vegfr1-3 pdgfα/β
8
months
7
patients
7
nintedanib
5
identify molecular
4
median pfs
4
pfs 161
4
sequencing ngs
4
ngs identify
4
associated worse
4

Altmetric Statistics

Similar Publications